The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy.
An unambiguous and specific HPLC assay was used to determine the pharmacokinetics of 7-hydroxymethotrexate (7-OHMTX) following the administration of moderate-dose methotrexate (MTX) 100 mg X m-2 to 37 patients with advanced head and neck cancer. There was marked interpatient variation but patient exposure to 7-OHMTX was considerable. There was, however, no correlation between the amount of 7-OHMTX produced and either tumour response or patient toxicity.
D002851:Chromatography, High Pressure Liquid; D006258:Head and Neck Neoplasms / Q000188:drug therapy; D006801:Humans; D007700:Kinetics; D008727:Methotrexate / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use*
C011864:7-hydroxymethotrexate; D008727:Methotrexate